Common TitlePREDICT-1
Official Title A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*5701) for Susceptibility to Abacavir Hypersensitivity
Phase Phase IIIA
ClinicalTrials.gov NCT00340080
Treatments
Abacavir
Abacavir
Tradename:ZiagenOther Names:ABCClass:Nucleoside Reverse Transcriptase Inhibitors (NRTI)Categories PharmacologyTreatment-NaiveTreatment-ExperiencedAdverse Effects
Funding
IndustryGlaxoSmithKline
References
- Mallal S, Phillips E, Carosi G, et al; PREDICT-1 Study Team. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358:568-79.